Supported by the Intramural Research Program of the National Eye Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. The sponsor and funding organization participated in the design and conduct of the study, data collection, management, analysis, and interpretation, and preparation, review, and approval of the manuscript.
Disclosure: S. Mukherjee, None; T. Arunachalam, None; C. Duic, None; M. Abraham, The Emmes Company (E); C. Orndahl, The Emmes Company (E); S. Menezes, The Emmes Company (E); E. Agrón, None; M. Pfau, Roche (R), Novartis (R), Inozyme Pharma (F), CenterVue (F); T. de Silva, Janssen Research and Development (E); C. Bailey, Bayer (R), Roche (R), Apellis (R), Alimera Sciences (R), Janssen (R), Boehringer-Ingelheim (R); A.T. Thavikulwat, None; S. Bellur, Sanofi Pharmaceuticals (E); S.R. Sadda, 4dMT (C), Abbvie/Allergan (C), Alexion (C), Alnylam (C), Amgen (C), Apellis (C), Astellas (C), Bayer (C), Bioepis (C), Biogen (C), Boerhinger Ingelheim (C), Catalyst (C), iCare/Centervue (C), Character (C), Eyepoint (C), Heidelberg (C, F), Roche/Genentech (C, R), IvericBio (C), Janssen (C), Neurotech (C), Nanoscope (C), NotalVision (C), Novartis (C, F), Optos (C, F, R), OcularTx (C), Oxurion (C), Regeneron (C), Samsung Bioepis (C), Nidek (F), Roche (F); Regeneron (C), RegenxBio (C), Carl Zeiss Meditec (R), Topcon (C), Samsung Bioepis (C), ARVO (S), Macula Society (S); E.Y. Chew, None; B.G. Jeffrey, None; W.T. Wong, Tiresias Biopharma Consulting LLC (E), Clearside Biomedical (C), Ocuphire Pharma (C); T.D.L. Keenan, None